探讨淋巴细胞与单核细胞比值（LMR）和CD163肿瘤相关巨噬细胞（TAM）对弥漫性大B细胞淋巴瘤（DLBCL）患者预后的价值。收集63例初诊DLBCL患者的外周血和淋巴结组织。 。 LMR是根据血常规检查结果计算外周血中淋巴细胞和单核细胞的数量。免疫组化法检测淋巴结CD163 TAM水平。通过ROC曲线确定LMR和CD163 TAM的截止值，分析LMR和CD163 TAM对DLBCL患者的预后价值。 63例初诊DLBCL患者的LMR水平为3.69±1.71，中位值为CD163 TAM 为 26/HPF。 CD163 TAM的数量与LMR呈负相关（r=-0.58），与单核细胞计数呈正相关（r=0.46）。 ROC曲线确定的LMR和CD163 TAM的截止值分别为2.95和29/HPF，据此将患者分为低LMR组和高LMR组，以及低CD163 TAM组和高LMR组。 CD163 TAM 组。低LMR组临床分期III-IV期、IPI评分3-5分、骨髓浸润的患者比例高于高LMR组（P < 0.05）。高CD163 TAM组临床分期III-IV期、IPI评分3-5分、LDH水平升高和骨髓浸润的患者比例高于低CD163 TAM组（P < 0.05）。 LMR 与 OS 呈正相关（r =0.43），CD163 TAM 与 OS 呈负相关（r =-0.65）。低LMR、高CD163 TAM的DLBCL患者OS较短（P < 0.05）。低LMR、高CD163 TAM可作为DLBCL患者预后不良的生物标志物。

To investigate the prognostic value of lymphocyte-to-monocyte ratio (LMR) and CD163+tumor-associated macrophages (TAM) in patients with diffuse large B cell lymphoma (DLBCL).Peripheral blood and lymph node tissues were collected from 63 newly diagnosed DLBCL patients. LMR was calculated by the number of lymphocytes and monocytes in peripheral blood from the result of blood routine examination. The level of CD163+TAM in lymph nodes was detected by immunohistochemistry. The cut-off values of LMR and CD163+TAM were determined by ROC curves, and the prognostic value of LMR and CD163+TAM in DLBCL patients was analyzed.The LMR level of 63 newly diagnosed DLBCL patients was 3.69±1.71, and the median value of CD163+TAM was 26/HPF. The number of CD163+TAM was negatively correlated with LMR (r =-0.58) and positively correlated with monocyte count (r =0.46). The cut-off values of LMR and CD163+TAM determined by ROC curve were 2.95 and 29/HPF, respectively, and based on this, the patients were divided into low LMR group and high LMR group, as well as low CD163+TAM group and high CD163+TAM group. The proportion of patients with clinical stage III-IV, IPI score 3-5 and bone marrow infiltration in the low LMR group were higher than those in the high LMR group (P < 0.05). The proportion of patients with clinical stage III-IV, IPI score 3-5, elevated LDH level and bone marrow infiltration in the high CD163+TAM group were higher than those in the low CD163+TAM group (P < 0.05). There was a positive correlation between LMR and OS (r =0.43) and a negative correlation between CD163+TAM and OS (r =-0.65). DLBCL patients with low LMR and high CD163+TAM had shorter OS (P < 0.05).Low LMR and high CD163+TAM can be used as biological markers for poor prognosis of DLBCL patients.